Send to

Choose Destination
J Neuroimmunol. 2011 Apr;233(1-2):221-7. doi: 10.1016/j.jneuroim.2010.12.001. Epub 2011 Jan 15.

Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression.

Author information

P. K. Anokhin Institute of Normal Physiology RAMS, Mohovaya St. 11, Building 4, 125009 Moscow, Russia.

Erratum in

  • J Neuroimmunol. 2014 Mar 15;268(1-2):99. Bocharova, Olga R [corrected to Bocharova, Olga A].


The aim was to ascertain any possible linkage between humoral immune responses to principal biomarkers (α-synuclein monomers, its toxic oligomers or fibrils, dopamine and S100B) and cellular immunity in Parkinson's disease development. There were elevated autoantibody titers to α-synuclein monomers, oligomers plus fibrils in 72%, 56%, and 17% of Parkinsonian patients respectively with a 5-year disease duration. Additionally, there were increased titers to dopamine and S100B (96% and 89%) in the 5-year patient group. All of these values subsided in 10-year sufferers. Furthermore, CD3+, CD4+, CD8+ T-lymphocyte and B-lymphocyte subsets declined in the patient cohort during Parkinsonism indicating disease associated reductions in these lymphocyte subsets.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center